Lancet
04/25/2002
By Harvey McConnell
Vaccines against hepatitis C are needed to curb the high rate of infection among injection-drug users, researchers say.
These vaccines should be tested in a bid to reduce the burden of liver disease associated with hepatitis C virus (HCV) infection, declares Dr David Thomas and colleagues at Johns Hopkins School of Medicine, Baltimore, Maryland, United States.
Nearly four million people in the United States, and 170 million people worldwide, have been infected with hepatitis C virus (HCV). An estimated 85 percent develop persistent infection and are at risk of long-term complications, including liver cirrhosis and hepatocellular carcinoma.
A sustained response rate of around 40 percent has been found in treatment of HCV with interferon-and ribavirin, and this rate will probably improve in the next decade with the advent of more effective antiretroviral treatments. However, the costs of such therapy means vaccination is an important alternative way to control disease, as vaccine effectiveness has been demonstrated in treatment of hepatitis B virus infection.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!